aminolevulinic acid (ALA PDT) / Shanghai Fudan-Zhangjiang - LARVOL DELTA

FIRST PATIENT ENROLLED IN CONFIRMATORY CLINICAL TRIAL OF AMINOLEVULINIC ACID HYDROCHLORIDE GRANULES FOR INTRAOPERATIVE VISUALISATION OF BLADDER CANCER (HKEXnews) - "The first patient in the confirmatory clinical trial of aminolevulinic acid hydrochloride granules (the 'Drug') for visualization of non-muscular invasive bladder cancer during transurethral resection of bladder tumor (the 'Study') has recently been successfully enrolled in the Study....The Study was received the approval for the confirmatory clinical trial application in 2024. The Study aims to evaluate its effectiveness and safety of aminolevulinic acid hydrochloride granules for visualization of non-muscular invasive bladder cancer during transurethral resection of bladder tumor."

Trial status • Bladder Cancer

Results of a randomized, double-blind, placebo-controlled phase II clinical trial of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) in moderate to severe acne vulgaris (ESDR 2024) - "Treatment groups outperformed placebo, but no significant differences distinguished the three groups. Both in the high and low dose group, topical adverse reactions were generally well tolerated."

Clinical • P2 data • Acne Vulgaris • Dermatology

Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA） (clinicaltrials.gov) - P3 | N=80 | Recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection (clinicaltrials.gov) - P2 | N=119 | Completed | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

New P2 trial • Gynecology • Human Papillomavirus Infection • Infectious Disease • Oncology

Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA） (clinicaltrials.gov) - P3 | N=80 | Not yet recruiting | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

New P3 trial • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

Pharmacokinetics and Safety of ALA in Acne Vulgaris (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting ➔ Completed

Trial completion • Acne Vulgaris • Dermatology